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Abstract: Patients with celiac disease (CD) frequently suffer from iron deficiency anemia (IDA)
and may benefit from iron supplementation. However, intolerance to iron sulfate and duodenal
atrophy could reduce the efficacy of this supplementation. This study evaluated the efficacy of
a new sucrosomial iron formulation in patients with CD. Consecutive patients with CD and IDA
were divided into two groups: patients with a known intolerance to iron sulfate were treated with
sucrosomial iron (30 mg of iron/day), while those receiving iron supplementation for the first time
were assigned to iron sulfate (105 mg of iron/day). Forty-three patients were enrolled (38 females,
mean age 49 ± 9 years). After a follow-up of 90 days both groups showed an increase in Hb levels
compared to baseline (+10.1% and +16.2% for sucrosomial and sulfate groups, respectively), and a
significant improvement in all iron parameters, with no statistical difference between the two groups.
Patients treated with sucrosomial iron reported a lower severity of abdominal symptoms, such as
abdominal and epigastric pain, abdominal bloating, and constipation, and a higher increase in general
well-being (+33% vs. +21%) compared to the iron sulfate group. Sucrosomial iron can be effective
in providing iron supplementation in difficult-to-treat populations, such as patients with CD, IDA,
and known intolerance to iron sulfate.
Keywords: sucrosomial iron; iron sulfate; celiac disease; iron deficiency anemia
1. Introduction
Celiac disease (CD) is a common autoimmune disease of the small intestine (SI), with a worldwide
prevalence of 1% in Western countries [1–7]. Notably, patients with CD frequently present with iron
deficiency anemia (IDA), which usually reverts with adoption of a gluten-free diet (GFD) and subsequent
normalization of the SI mucosa [8,9]. However, some patients present persistent IDA despite GFD.
A number of factors may contribute to this scenario, such as persistence of a negative balance between iron
intake and loss, persistence of villous atrophy despite correct GFD, or presence of a genetic background
that reduces iron absorption [10]. These subjects may benefit from iron supplementation, although both
the SI damage and the low tolerance to iron sulfate could reduce its efficacy [11]. Response to iron
supplementation could be enhanced by using a tolerated iron form or an iron formulation able to increase
intestinal absorption through the intestinal barrier, thus overcoming mucosal atrophy [12]. Noteworthy,
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a recent consensus paper states that new oral iron products may be efficacious in patients who are
intolerant or non-responsive to conventional iron salts, and in those with contraindications to intravenous
(IV) iron [13].
Sucrosomial iron (Sideral® Forte, Pharmanutra, Pisa, Italy) is a preparation of ferric pyrophosphate
covered by a phospholipids and sucrester membrane, which proved to be effective in the nutritional
supplementation of oncological patients, in subjects affected from chronic kidney disease, in pregnant
women, and after bariatric surgery [13–19]. This new formulation shows high gastrointestinal absorption
and bioavailability, with a low incidence of side effects thanks to the absence of a direct contact with
the intestinal mucosa [14]. Indeed, this formulation consists of a low, non-toxic dose of sucresters,
which protect iron from the acid environment of the stomach and increase its permeability, thus allowing
higher absorption rates [13,14]. In addition, sucrosomial iron can be absorbed across intestinal epithelium
by an alternative route, non-mediated by the DMT-1 carrier [20], which may contribute to the reduction of
side effects and the prevention of iron instability in the gastrointestinal tract [20]. Therefore, sucrosomial
iron might represent a promising new strategy of iron replacement in patients with CD, but evidence
supporting its use in this setting is required. In particular, this nutritional supplementation may have
a role in patients with CD with damaged intestinal mucosa, who are often intolerant to standard iron
formulations and, therefore, may need to interrupt this supplementation [12].
This prospective study investigates nutritional supplementation with sucrosomial iron in patients
with CD and IDA, and a previous therapeutic failure with oral iron sulfate supplementation.
2. Patients and Methods
2.1. Study Setting and Design
This was a prospective monocentric study, conducted at the Center for Prevention and Diagnosis
of Celiac Disease of the Fondazione IRCCS Ca’ Granda Milan, Italy. All patients, enrolled from October
2014 to April 2016, signed an informed consent form before enrolment and the local ethics committee
approved the study design (protocol number 1892). The trial has been registered on ClinicalTrials.gov,
number NCT02916654.
Consecutive adult patients with treated CD and concomitant IDA, according to current guidelines on
CD diagnosis and IDA [21], were eligible to this study. IDA diagnosis was established based on laboratory
data, according to Beutler and Waalen [22], i.e., hemoglobin (Hb) < 12.2 g/dL in women and <13.7 g/dL
in men. IDA was identified on the basis of serum iron, ferritin < 20 ng/mL and transferrin saturation
< 20%. Other types of anemia, as related to folic acid or B12 vitamin deficiency, were excluded to avoid
a confounding effect. All patients followed a strict GFD for at least 12 months with normalization of
anti-transglutaminase IgA. Patients with a B12 vitamin or folic acid deficiency, reporting a voluntary
ingestion of gluten-containing food, with persistence of circulating anti transglutaminase IgA, suggesting
gluten ingestion, or with hematological diseases were excluded from the study. When indicated, patients
underwent a second duodenal biopsy (at least four oriented duodenal specimens) or other endoscopic
investigations, such as capsule endoscopy or colonoscopy.
Consecutive eligible patients were assigned to either ferrous sulfate or sucrosomial iron treatment
depending on their previously reported tolerance to ferrous sulfate. The first group, reporting a previous
intolerance to ferrous sulfate leading to a suspension of therapy, was treated with sucrosomial iron
(Sideral® Forte, Pharmantra SpA, Pisa, Italy), 30 mg of elemental iron per day; the second group was
composed by patients tolerant to ferrous sulfate or naïve to iron supplementation who were administered
iron sulfate tablets (Ferrograd®, Teofarma, Pavia, Italy), 105 mg of elemental iron per day. We decided
to use two different doses to counterbalance the higher absorption rate of sucrosomial formulation,
as reported by Fabiano et al. in a recent comparative study on in vivo and ex vivo absorption of different
iron formulations [20]. Patients’ clinical and demographic characteristics, including duration of GFD and
duodenal histology (graded by means of the Marsh-Oberhuber scale [23]), when available, were evaluated.
All patients were followed for a period of 90 days, during which three visits comprehensive of blood tests
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were performed: at baseline (T0), at 45 days (T45), and at 90 days (T90). Therapy compliance was verified
during the clinical visits by an interview with the physician.
2.2. Evaluations
The following serological parameters were measured to evaluate the iron status: hemoglobin (Hb,
g/dL), mean corpuscular volume (MCV, fL), hematocrit (%) (Sysmex XN-9000 automated hematology
analyzer, Sysmex, Kobe, Japan), iron (Quantitative ELISA, Roche, Basilea, Switzerland, expressed
as µg/dL), ferritin (chemiluminescent method expressed as ng/mL), quantitative determination of
transferrin (mg/dL) and transferring saturation calculated following the formula (iron (transferrin × 1.42)
× 100). Iron parameters were measured at T0, T45, and T90.
The severity of possible symptoms associated with both treatments, assessed by a 10 cm visual
analogic scale (VAS) evaluating diarrhea, constipation, epigastric and abdominal pain, stool consistency,
and general well-being were also measured at T0, T45, and T90.
Smoking habits, menstrual losses, and Helicobacter pylori infection (13C urea breath test) were
also evaluated. All the evaluations were performed directly by the physicians during baseline and
follow-up visits and through the administration of questionnaires.
An analysis of Hb levels by stratifying patients according to their Marsh grade (0–2 vs. 3a, 3b, 3c,
i.e., duodenal normotrophic mucosa vs. duodenal atrophy) was also performed.
2.3. Statistical Analysis
All data were analyzed by descriptive statistics and presented as mean ± standard deviation (SD)
and a p-value < 0.05 was considered statistically significant. Kolmogorov-Smirnov’s test was used to
assess the normal distribution of data. Intra- and inter-group comparisons were performed by the
chi-square test or the Fisher’s exact test, as appropriate for discrete variables, and by the Student’s
t-test or the Mann-Whitney test, as appropriate for continuous variables. Two-way ANOVA was used
for variance analysis and further non-parametric tests included Friedman and Wilcoxon tests were
performed. Statistical significance was further confirmed using Tukey’s test or Mann-Whitney.
Statistical analysis was performed by the SPSS software (version 19, IBM, Armonk, NY, USA).
3. Results
3.1. Patient Populations
In total, 43 patients were enrolled (38 females, age at enrolment 41 ± 10 years, age at CD diagnosis
35± 11 years, years on a GFD 8± 7 years). Of these, 24 (55%) reported previous side effects and intolerance
to iron sulfate and, thus, received sucrosomial iron. In the sucrosomial iron group, nine patients (32%)
had an atrophic lesion at duodenal histology (Marsh grade 3a, b or c), as compared to 6 subjects (41%)
in the iron sulfate group (Table 1). In addition to CD, in the sucrosomial iron group 1 patient presented
autoimmune hepatitis, 1 presented Sjogren disease, and 7 presented Hashimoto thyroiditis; in the iron
sulfate group, 6 patients had Hashimoto thyroiditis.
Table 1. Clinical and demographic characteristics of enrolled patients.
Patients’ Characteristics Sucrosomial Iron Group (n = 24) Iron Sulfate Group (n = 19) p
Sex (n, male/female) 1/23 1/18 1.00
Age at enrollment (years) 43 ± 10 40 ± 8 0.22
Age at diagnosis (years) 38 ± 8 31 ± 12 0.06
GFD duration (years) 6 ± 5 9 ± 9 0.26
BMI 21 ± 2 22 ± 3 0.34
Smokers, n (%) 0 (0%) 2 (16%) 0.08
Nutrients 2018, 10, 330 4 of 9
Table 1. Cont.
Patients’ Characteristics Sucrosomial Iron Group (n = 24) Iron Sulfate Group (n = 19) p
Menstrual cycle duration (days) 5 ± 2 4 ± 2 0.20
Tampons, n 26 ± 17 21 ± 13 0.28
Hp positivity, n (%) 2 (8%) 2 (10%) 1.00
Colonoscopy 16 7 0.051
MARSH Grade, n (%) 22 (92%) 17 (89%) 0.13
0 7 (32%) 7 (41%)
1 6 (27%) 2 (12%)
2 - 1 (6%)
3a 5 (23%) 5 (29%)
3b 4 (18%) -
3c - 2 (12%)
Comorbidities, n (%) 9 (37.5%) 5 (26%) 0.44
BMI, body mass index; GFD, gluten-free diet; Hp, Helicobacter pylori. Chi-square test and Fisher’s exact test were
used for discrete variables; Student’s t-test and the Mann-Whitney test were used for continuous variables.
3.2. Iron Parameters
Table 2 summarizes iron parameters measured in the two groups at the beginning and at the end
of the iron supplementation. At T0 the enrolled CD cohort presented an Hb of 10.9 ± 0.7 g/dL for the
sucrosomial iron group, and Hb of 11.0 ± 0.7 g/dL for the iron sulfate group (Table 2). A mean Hb
increase versus baseline of 10.1% and 16.2%, was obtained for the sucrosomial iron and iron sulfate
group, respectively (p = 0.002). In total, 7 patients receiving sucrosomial iron (30%) and 10 on iron
sulfate (60%) showed a >15% increase in Hb concentration at T90, compared to T0 (p = 0.2). While all
patients had abnormal Hb values at baseline, at T90, a similar proportion of patients in the two groups
presented Hb values within the range of normality (70% vs. 82%, p = n.s.). These results were obtained
despite a 33% lower dose of sucrosomial iron compared to iron sulfate.
Table 2. Blood tests and iron parameters of enrolled patients with CD. Statistical analysis was performed
to evaluate the difference before and after therapy (P(T0–T90)) and between the two types of iron
supplementation at the end of the treatment (P(groups)).
Sucrosomial Iron Group (n = 23) Iron Sulfate Group (n = 17)
T0 T45 T90 P(T0–T90) T0 T45 T90 P(T0–T90) P(groups)
Hemoglobin (g/dL) 10.9 ± 0.7 11.7 ± 0.7 12.0 ± 0.7 0.03 11.0 ± 1.0 12.2 ± 1.0 12.9 ± 1.1 0.002 0.03
MCV (fL) 76.4 ± 5 81.1 ± 5.2 83.5 ± 5.0 0.002 74.2 ± 7.5 81.8 ± 7.3 83.7 ± 6.8 0.008 0.33
Hematocrit (%) 34.2 ± 2.5 36.2 ± 2.9 36.7 ± 3.0 0.08 35.4 ± 3.9 37.6 ± 2.6 38.8 ± 2.6 0.008 0.06
Serum Iron (µg/dL) 41.8 ± 24.0 59.0 ± 29.0 59.9 ± 35.4 0.8 44.9 ± 29.9 66.2 ± 28.0 73.2 ± 21.9 0.14 0.28
Ferritin (ng/mL) 10.7 ± 12.4 16.2 ± 15.2 18.2 ± 15.7 0.04 13.4 ± 15.8 51.2 ± 82.4 59.1 ± 76.3 0.007 0.0001
Transferrin (mg/dL) 311.5 ± 51.3 302.4 ± 46.6 292.1 ± 51.0 0.007 320.6 ± 50.5 293.0 ± 55.4 271.6 ± 40.7 0.006 0.2
Transferrin sat. (%) 10.0 ± 6.4 14.8 ± 9.0 14.8 ± 8.2 0.8 10.6 ± 8.4 16.8 ± 8.0 19.6 ± 6.6 0.03 0.04
MCV, mean corpuscular volume. Chi-square test and Fisher’s exact test were used for discrete variables; Student’s
t-test and the Mann-Whitney test were used for continuous variables.
All other iron parameters significantly improved with both treatments, compared to baseline
values (Table 2). No significant differences between groups were reported in any parameter, with the
exception of ferritin, which was higher in patients on iron sulfate (Table 2). In both groups, at T90,
most patients presented normalized values of all iron parameters (Table 2).
Notably, these results were not influenced by excessive supplementation or blood loss during
the course of the study: no transfusions nor other blood supplements were administered to patients
during the study, while blood loss in the female population was assessed by measuring the mean
number of days of the menstrual cycle (see Table 1).
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3.3. Effects in Patients with Mucosal Damage
Overall, Hb concentration similarly increased in patients with MARSH grade 0–2 and in those
with grade 3a-b-c (MARSH 0–2: 11.2 ± 0.8 g/dL at baseline vs. 12.5 ± 1.0 g/dL at T90, p = 0.0001;
MARSH 3a-b-c: 10.4 ± 0.7 g/dL at baseline vs. 11.9 ± 0.9 g/dL at T90, p = 0.001).
In patients with MARSH grade 3a-b-c, a similar increase in Hb concentration at T90 was reported in
the two groups compared to baseline, despite the use of sucrosomial iron of 1/3 of the iron sulfate dose
(sucrosomial iron: from 10.6 ± 0.6 g/dL at T0 to 11.8 ± 0.9 g/dL at T90, +11.1%, p = 0.15; iron sulfate:
from 10.2 ± 0.9 g/dL at T0 to 12.0 ± 0.9 g/dL at T90, +18%, p = 0.03). No difference was found between
the Hb concentrations at T90 of patients treated with sucrosomial iron vs. iron sulfate and showing a
MARSH grade 3a-b-c duodenal lesion (11.8 ± 0.9 g/dL vs. 12.0 ± 0.9 g/dL, p = 0.28) (Figure 1).
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3.4. Symptoms and Tolerability
verall, four patients fro the enrolled cohort reported an adverse event: 2 patients at T45
(abdo inal colic in the sucroso ial iron group and nausea in the iron sulfate group) and 2 at T90
(vaginal itching in the sucrosomial iron group and dyspepsia plus gastro-esophageal reflux in the iron
sulfate group). Both adverse events in the iron sulfate group were judged as potentially correlated
with treatment; conversely both events in the sucrosomial iron group were considered unrelated
to treatment.
Table 3 su arizes the results of sy pto s assess ent of the t o groups throughout the
study period. Overall, no significant differences between groups were reported at any ti e-point,
although a lower severity of abdominal and epigastric pain, abdominal bloating, and constipation with
sucrosomial iron was reported. Similarly, a greater general well-being was reported with sucrosomial
iron, co pared to iron sulfate, with similar values in the two groups at T90 (% variation at T90 vs.
baseline: +33% vs. +21%; Figure 2).
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Table 3. Gastrointestinal symptoms.
Sucrosomial Iron Group (n = 23) Iron Sulfate Group (n = 17)
T0 T45 T90 P(T0–T90) T0 T45 T90 P(T0–T90) P(groups)
Abdominal Pain 1.9 ± 2.1 2.2 ± 2.2 2.2 ± 2.7 0.07 1.9 ± 1.6 2.7 ± 2.8 2.9 ± 2.5 0.07 0.52
Epigastric Pain 1.8 ± 2.4 1.6 ± 2.4 1.3 ± 1.7 0.7 1.9 ± 2.1 2.4 ± 2.3 2.3 ± 1.8 0.7 0.31
Abdominal Bloating 4.9 ± 3.1 4.4 ± 3.2 4.2 ± 3.5 0.9 3.7 ± 2.5 4.2 ± 3.1 4.1 ± 2.9 0.9 0.6
Diarrhea 1.1 ± 1.6 2.3 ± 2.7 2.0 ± 2.3 0.12 1.5 ± 1.3 2.4 ± 2.0 2.3 ± 1.6 0.11 0.57
Constipation 2.6 ± 3.0 2.0 ± 2.6 1.9 ± 2.8 0.5 2.0 ± 2.2 2.2 ± 2.5 2.8 ± 2.6 0.7 0.8
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Two patients in the sucrosomial iron group (9%) and 4 treated with iron sulfate (23%) prematurely
discontinued therapy. In the sucrosomial iron group discontinuation was due to adverse events for
1 patient and to patient’s decision for the other, while in the iron sulfate group discontinuation was
due to poor efficacy (n = 2), adverse events, and patient’s decision (n = 1 each).
4. Discussion
Iron supplementation is frequently required in patients with CD, who often present poor iron
absorption due to intestinal disease [11]. To this end, oral iron formulations are often preferred over IV
formulations, due to increased convenience of use and patients’ preference [13]. However, absorption of
standard oral iron formulation may be poor in patients with CD due to intestinal malabsorption [13] and
they can frequently present side effects, such as abdominal pain, bloating, diarrhea, and constipation.
In this study, conducted in a field-practice scenario, we show that sucrosomial iron, an innovative oral
iron formulation, is an effective alternative to standard ferrous sulfate in providing iron supplementation
in difficult-to-treat populations, such as patients with CD and IDA who are intolerant to iron sulfate.
Sucrosomial iron may be particularly suitable for patients with CD and IDA since its innovative
formulation does allow good intestinal absorption in patients with inflamed mucosa or gastrointestinal
diseases [13].
Fabiano et al. have previously shown that sucrosomial iron has a higher intestinal permeability
compared to other iron formulations. Their study showed that supplementation with sucrosomial
iron leads to an increased internalization of Fe3+ by intestinal Caco-2 cells in vitro, and enhanced
Fe3+ absorption across rat intestinal epithelium compared to other formulations containing ferric
pyrophosphate in ex vivo experimentation. Moreover, this new formulation presents some advantages
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over the standard ones, such as an increase in ferric iron retention in simulated gastric fluid conditions,
a protective action on ferric iron from intestinal enzyme reduction, and promotion of intestinal
absorption independently of the DMT-1 carrier [20].
In our study, iron parameters showed, overall, a similar improvement in the two groups, with the
wide majority of patients returning to physiological values of the various parameters assessed after 90 days
of iron supplementation. Despite this similar outcome it is important to note that patients receiving
sucrosomial iron had experienced prior failure with iron sulfate and may, therefore, be considered a more
challenging-to-treat population compared to the evaluated controls. Moreover, these patients received a
33% lower dose of iron compared to the control group. Remarkably, with both treatments, increased Hb
concentration was also observed in patients with more severe atrophic mucosal damage (MARSH 3a-b-c
grade).
No tolerability concerns were reported in either group. However, it is important to notice that
sucrosomial iron therapy was associated with less severe gastrointestinal symptoms and enhanced general
well-being, as compared to baseline. On the other hand, treatment with iron sulfate was associated with
an increased severity of gastrointestinal symptoms through the study period. These findings may be
due, at least in part, to the lower dosage of iron required to exert the same effect with the sucrosomial
technology as compared to standard supplementation with iron sulfate, [14], but also to the protection of
the iron within the phospholipids and sucrester matrix.
Our results are in line with those reported in a recent study where oral sucrosomial iron was
compared to intravenous iron supplementation in a group of women of childbearing age undergoing
gastric bypass and requiring chronic iron therapy [19]. Ciudin et al. observed that oral sucrosomial
iron was as effective as intravenous iron sucrose in increasing iron parameters such as Hb, ferritin,
and transferrin saturation after 90 days of treatment. Moreover, no adverse effects were reported with
either form of supplementation, thus suggesting that sucrosomial iron represents a safe and effective
alternative in patients who require parenteral treatment after bariatric surgery [19].
5. Conclusions
We are aware that our study has a number of limitations. Compared to previous studies, our research
had an overall short follow-up period and a relatively small sample size, which may result in decreased
statistical power, marginal significance for demographic factors, and weaker inference in conclusions.
We acknowledge the importance of conducting larger and longer studies on different populations of
patients with CD to further evaluate our findings. However, the observed efficacy of sucrosomial iron,
together with the lack of associated symptoms in a difficult-to-treat population may have relevance to
clinical practice. Indeed, adherence to treatment remains a major determinant of good clinical outcomes in
patients with CD who need iron supplementation [24]. We believe that sucrosomial iron holds the potential
to increase adherence to iron supplementation in patients with CD and IDA, given the improvement of
bothersome gastrointestinal symptoms associated with this therapy.
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